We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+8.93%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.4B
AUM Growth
-$406M
Cap. Flow
-$163M
Cap. Flow %
-1.13%
Top 10 Hldgs %
24.27%
Holding
957
New
98
Increased
341
Reduced
353
Closed
82

Top Buys

Rank Stock Value
1
BZ icon
Kanzhun
BZ
+$45.9M
2
STKL
SunOpta
STKL
+$45M
3
ZTO icon
ZTO Express
ZTO
+$44.4M
4
JPM icon
JPMorgan Chase
JPM
+$39.9M
5
XIFR
XPLR Infrastructure LP
XIFR
+$36.1M

Top Sells

Rank Stock Value
1
MELI icon
Mercado Libre
MELI
+$79.9M
2
MSFT icon
Microsoft
MSFT
+$58.5M
3
VERU icon
Veru
VERU
+$53.9M
4
PG icon
Procter & Gamble
PG
+$50.5M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$37M

Sector Composition

Rank Sector Weight
1 Healthcare 30.95%
2 Technology 26.5%
3 Financials 9.1%
4 Consumer Discretionary 8.02%
5 Industrials 7.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CRBU icon
776
Caribou Biosciences
CRBU
$146M
$418K ﹤0.01%
+85,556
New +$533K
AVIR icon
777
Atea Pharmaceuticals
AVIR
$370M
$417K ﹤0.01%
135,316
-58,640
-30% -$238K
PCVX icon
778
Vaxcyte
PCVX
$7.65B
$416K ﹤0.01%
+12,070
New +$512K
NEO icon
779
NeoGenomics
NEO
$1.99B
$414K ﹤0.01%
25,851
-51,028
-66% -$727K
BMBL icon
780
Bumble
BMBL
$387M
$412K ﹤0.01%
+22,888
New +$517K
CDXS icon
781
Codexis
CDXS
$158M
$412K ﹤0.01%
108,061
-50,914
-32% -$267K
ACRS icon
782
Aclaris Therapeutics
ACRS
$715M
$411K ﹤0.01%
55,208
-3,439
-6% -$43.6K
RSG icon
783
Republic Services
RSG
$67.4B
$407K ﹤0.01%
3,273
-188,094
-98% -$24M
FNV icon
784
Franco-Nevada
FNV
$41.3B
$407K ﹤0.01%
3,036
-207
-6% -$28.9K
RIVN icon
785
Rivian
RIVN
$23.6B
$405K ﹤0.01%
28,422
+10,913
+62% +$184K
ANAB icon
786
AnaptysBio
ANAB
$1.54B
$405K ﹤0.01%
+20,205
New +$491K
MDRX
787
DELISTED
Veradigm Inc. Common Stock
MDRX
$403K ﹤0.01%
+33,580
New +$544K
WRK
788
DELISTED
WestRock Company
WRK
$402K ﹤0.01%
14,334
-2,817
-16% -$93K
BILL icon
789
BILL Holdings
BILL
$4.72B
$400K ﹤0.01%
5,357
-5,557
-51% -$515K
ARW icon
790
Arrow Electronics
ARW
$10.5B
$398K ﹤0.01%
3,465
-891
-20% -$106K
ATRA icon
791
Atara Biotherapeutics
ATRA
$72.6M
$390K ﹤0.01%
5,846
-1,796
-24% -$174K
ALEC icon
792
Alector
ALEC
$169M
$390K ﹤0.01%
68,368
-29,570
-30% -$241K
GTN icon
793
Gray Television
GTN
$437M
$382K ﹤0.01%
47,595
+14,860
+45% +$166K
HR icon
794
Healthcare Realty
HR
$7.56B
$381K ﹤0.01%
+21,438
New +$432K
NVTA
795
DELISTED
Invitae Corporation
NVTA
$380K ﹤0.01%
306,051
-57,320
-16% -$113K
AMC icon
796
AMC Entertainment Holdings
AMC
$2.45B
$379K ﹤0.01%
8,229
+2,142
+35% +$113K
AAP icon
797
Advance Auto Parts
AAP
$3.53B
$374K ﹤0.01%
+3,338
New +$467K
ANGO icon
798
AngioDynamics
ANGO
$605M
$371K ﹤0.01%
39,009
-34,384
-47% -$440K
RBA icon
799
RB Global
RBA
$21.5B
$368K ﹤0.01%
7,119
-1,955
-22% -$115K
HAS icon
800
Hasbro
HAS
$13.5B
$365K ﹤0.01%
7,391
-48,848
-87% -$2.79M

Similar funds

Candriam SCA's Q1 2023 Portfolio in Review

As of Q1 2023, Candriam SCA held 957 positions worth $14.4B, down 2.7% from $14.8B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Candriam SCA's Q1 2023 filing shows 98 new, 341 increased, 353 reduced and 82 closed positions. Its largest new stake was Kanzhun: 2,106,130 shares worth $36.9M. The largest sale was Mercado Libre, an estimated $79.9M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 33% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2023 buy was Kanzhun: 2,106,130 shares worth $36.9M.
  • Candriam SCA added most to SunOpta in Q1 2023, an estimated $45M increase.
  • Candriam SCA's biggest Q1 2023 reduction was Mercado Libre, cutting an estimated $79.9M.
  • Candriam SCA fully exited Veru in Q1 2023, selling an estimated $53.9M.
  • Candriam SCA's ten largest holdings make up 24% of its $14.4B portfolio in Q1 2023.
  • Candriam SCA opened 98 new positions and closed 82 in Q1 2023.
  • Candriam SCA's portfolio value fell 2.7% quarter-over-quarter to $14.4B.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.